Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 MK-4280A (favezelimab + pembrolizumab) vs standard of care in previously treated metastatic PD-L1 positive colorectal cancer
jRCT2031210482Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in colorectal adenocarcinoma comparing MK-4280A arm with Standard of care arm (2 arms). Primary endpoint: Overall survival. Started Jan 2022; status: completed.
02
Drugs
favezelimab + pembrolizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031210482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210482.